

Message

---

**From:** Newhouse, Kathleen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5F019C8179304045ACD61BC05B571FB0-NEWHOUSE, KATHLEEN]  
**Sent:** 1/26/2016 11:02:06 PM  
**To:** Sanya Petrovic [sanya.petrovic@hc-sc.gc.ca]; Angela Li-Muller [angela.li-muller@hc-sc.gc.ca]  
**Subject:** RE: b(a)p dermal slope factor

Hi Sanya and Angela,

Quite a while back, Lindsay Smith-Munoz gave me your names as contacts if I wanted information on Health Canada's BaP dermal slope factor efforts. I thought I would check in and see where your version of the benzo[a]pyrene dermal slope factor is in the pipeline and how it going. I apologize if it has been posted and I missed it.

As for EPA's BaP dermal slope factor, our external peer review panel has posted a draft report and will hopefully post the final report in about a month or so. You can find their draft report here:

<http://yosemite.epa.gov/sab/sabproduct.nsf/0/4dcfd0e5f45a8cad85257b65005b17c8!OpenDocument&TableRow=2.2#2.>

If I were to sum up their (draft) advice on our dermal slope factor, I'd say they commended EPA for taking steps to derive this value (as they agree on its importance), but that they disagree with our approaches. Unfortunately for us, they did not give us specific advice on our sticky issues (like how to extrapolate between mice and humans).

It has not been announced yet, but the IRIS program is planning on having a public meeting with several outside dermal experts in late June. We are hoping to get some more specific advice that will help us move forward with our efforts to develop a dermal slope factor for BaP.

Any information you can share with me about your efforts on this front would be much appreciated.  
Thanks!

Kathleen

Kathleen Newhouse, MS, DABT  
Acting Associate for Chemical Assessment | Toxic Effects Branch | IRIS Division  
National Center for Environmental Assessment | Office of Research and Development  
U.S. Environmental Protection Agency

Physical location: EPA Region X | M/S OEA-095 office #14J14 | 1200 Sixth Ave Suite 1400 | Seattle, Wa 98101  
206-553-1586 (Office: Tue, Thurs, Fri)  
Ex. 6 Personal Privacy (PP) (AWL: Mon, Wed)

---

**From:** Lindsay Smith-Munoz [mailto:lindsay.smith-munoz@hc-sc.gc.ca]  
**Sent:** Friday, March 28, 2014 2:07 PM  
**To:** Newhouse, Kathleen <Newhouse.Kathleen@epa.gov>  
**Cc:** Sanya Petrovic <sanya.petrovic@hc-sc.gc.ca>; Angela Li-Muller <angela.li-muller@hc-sc.gc.ca>  
**Subject:** RE: b(a)p dermal slope factor

Hi Kathleen,

This is the report I mentioned in our discussion. Please note it is a contractor report, not official Health Canada guidance. Today got a little busy with leaving checklists and cubicle cleaning, so if you want to discuss matters relating to b(a)p dermal risk you can contact Sanya Petrovic or Angela Li-Muller, cc'd on this message. I'll be sure to send you my new email from Stantec.

*(See attached file: HC\_Dermal\_Report\_FINAL\_20120227.pdf)*

Lindsay Smith-Munoz  
Human Health Risk Assessor  
Environmental Health Program  
Health Canada  
(204) 983-5690  
[lindsay.smith-munoz@hc-sc.gc.ca](mailto:lindsay.smith-munoz@hc-sc.gc.ca)